183 related articles for article (PubMed ID: 16381045)
1. Altering the regioselectivity of cytochrome P450 CYP102A3 of Bacillus subtilis by using a new versatile assay system.
Lentz O; Feenstra A; Habicher T; Hauer B; Schmid RD; Urlacher VB
Chembiochem; 2006 Feb; 7(2):345-50. PubMed ID: 16381045
[TBL] [Abstract][Full Text] [Related]
2. Expression, purification, and characterization of Bacillus subtilis cytochromes P450 CYP102A2 and CYP102A3: flavocytochrome homologues of P450 BM3 from Bacillus megaterium.
Gustafsson MC; Roitel O; Marshall KR; Noble MA; Chapman SK; Pessegueiro A; Fulco AJ; Cheesman MR; von Wachenfeldt C; Munro AW
Biochemistry; 2004 May; 43(18):5474-87. PubMed ID: 15122913
[TBL] [Abstract][Full Text] [Related]
3. Construction of a thermostable cytochrome P450 chimera derived from self-sufficient mesophilic parents.
Eiben S; Bartelmäs H; Urlacher VB
Appl Microbiol Biotechnol; 2007 Jul; 75(5):1055-61. PubMed ID: 17468867
[TBL] [Abstract][Full Text] [Related]
4. Substrate specificity of native and mutated cytochrome P450 (CYP102A3) from Bacillus subtilis.
Lentz O; Urlacher V; Schmid RD
J Biotechnol; 2004 Feb; 108(1):41-9. PubMed ID: 14741768
[TBL] [Abstract][Full Text] [Related]
5. Altering the regioselectivity of the subterminal fatty acid hydroxylase P450 BM-3 towards gamma- and delta-positions.
Dietrich M; Do TA; Schmid RD; Pleiss J; Urlacher VB
J Biotechnol; 2009 Jan; 139(1):115-7. PubMed ID: 18984016
[TBL] [Abstract][Full Text] [Related]
6. The bacterial P450 BM3: a prototype for a biocatalyst with human P450 activities.
Yun CH; Kim KH; Kim DH; Jung HC; Pan JG
Trends Biotechnol; 2007 Jul; 25(7):289-98. PubMed ID: 17532492
[TBL] [Abstract][Full Text] [Related]
7. Selective hydroxylation of highly branched fatty acids and their derivatives by CYP102A1 from Bacillus megaterium.
Budde M; Morr M; Schmid RD; Urlacher VB
Chembiochem; 2006 May; 7(5):789-94. PubMed ID: 16566047
[TBL] [Abstract][Full Text] [Related]
8. Filling a hole in cytochrome P450 BM3 improves substrate binding and catalytic efficiency.
Huang WC; Westlake AC; Maréchal JD; Joyce MG; Moody PC; Roberts GC
J Mol Biol; 2007 Oct; 373(3):633-51. PubMed ID: 17868686
[TBL] [Abstract][Full Text] [Related]
9. Regio- and enantioselective alkane hydroxylation with engineered cytochromes P450 BM-3.
Peters MW; Meinhold P; Glieder A; Arnold FH
J Am Chem Soc; 2003 Nov; 125(44):13442-50. PubMed ID: 14583039
[TBL] [Abstract][Full Text] [Related]
10. Cloning, expression and characterisation of CYP102A2, a self-sufficient P450 monooxygenase from Bacillus subtilis.
Budde M; Maurer SC; Schmid RD; Urlacher VB
Appl Microbiol Biotechnol; 2004 Dec; 66(2):180-6. PubMed ID: 15375636
[TBL] [Abstract][Full Text] [Related]
11. Obligatory intermolecular electron-transfer from FAD to FMN in dimeric P450BM-3.
Kitazume T; Haines DC; Estabrook RW; Chen B; Peterson JA
Biochemistry; 2007 Oct; 46(42):11892-901. PubMed ID: 17902705
[TBL] [Abstract][Full Text] [Related]
12. Sensitive assay for laboratory evolution of hydroxylases toward aromatic and heterocyclic compounds.
Wong TS; Wu N; Roccatano D; Zacharias M; Schwaneberg U
J Biomol Screen; 2005 Apr; 10(3):246-52. PubMed ID: 15809320
[TBL] [Abstract][Full Text] [Related]
13. Preparation of human metabolites of propranolol using laboratory-evolved bacterial cytochromes P450.
Otey CR; Bandara G; Lalonde J; Takahashi K; Arnold FH
Biotechnol Bioeng; 2006 Feb; 93(3):494-9. PubMed ID: 16224788
[TBL] [Abstract][Full Text] [Related]
14. Protein engineering of the cytochrome P450 monooxygenase from Bacillus megaterium.
Urlacher VB; Schmid RD
Methods Enzymol; 2004; 388():208-24. PubMed ID: 15289074
[No Abstract] [Full Text] [Related]
15. Evolved CYP102A1 (P450BM3) variants oxidise a range of non-natural substrates and offer new selectivity options.
Whitehouse CJ; Bell SG; Tufton HG; Kenny RJ; Ogilvie LC; Wong LL
Chem Commun (Camb); 2008 Feb; (8):966-8. PubMed ID: 18283351
[TBL] [Abstract][Full Text] [Related]
16. A continuous spectrophotometric assay for P450 BM-3, a fatty acid hydroxylating enzyme, and its mutant F87A.
Schwaneberg U; Schmidt-Dannert C; Schmitt J; Schmid RD
Anal Biochem; 1999 May; 269(2):359-66. PubMed ID: 10222011
[TBL] [Abstract][Full Text] [Related]
17. Toward understanding the inactivation mechanism of monooxygenase P450 BM-3 by organic cosolvents: a molecular dynamics simulation study.
Roccatano D; Wong TS; Schwaneberg U; Zacharias M
Biopolymers; 2006 Dec; 83(5):467-76. PubMed ID: 16862534
[TBL] [Abstract][Full Text] [Related]
18. Laboratory evolution of P450 BM3 for mediated electron transfer yielding an activity-improved and reductase-independent variant.
Nazor J; Dannenmann S; Adjei RO; Fordjour YB; Ghampson IT; Blanusa M; Roccatano D; Schwaneberg U
Protein Eng Des Sel; 2008 Jan; 21(1):29-35. PubMed ID: 18093991
[TBL] [Abstract][Full Text] [Related]
19. Bacillus megaterium CYP102A1 oxidation of acyl homoserine lactones and acyl homoserines.
Chowdhary PK; Keshavan N; Nguyen HQ; Peterson JA; González JE; Haines DC
Biochemistry; 2007 Dec; 46(50):14429-37. PubMed ID: 18020460
[TBL] [Abstract][Full Text] [Related]
20. Cobaltocene-mediated catalytic monooxygenation using holo and heme domain cytochrome P450 BM3.
Udit AK; Arnold FH; Gray HB
J Inorg Biochem; 2004 Sep; 98(9):1547-50. PubMed ID: 15337607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]